LIPI

Summary

LIPI (lipase I, HGNC:18821) is a protein-coding gene on chromosome 21q11.2, encoding Lipase member I (Q6XZB0). Hydrolyzes specifically phosphatidic acid (PA) to produce 2-acyl lysophosphatidic acid (LPA; a potent bioactive lipid mediator) and fatty acid.

The protein encoded by this gene is a phospholipase that hydrolyzes phosphatidic acid to produce lysophosphatidic acid. Defects in this gene are a cause of susceptibility to familial hypertrigliceridemia. This gene is also expressed at high levels in Ewing family tumor cells. Alternative splicing results in multiple transcript variants.

Source: NCBI Gene 149998 — RefSeq curated summary.

At a glance

• Gene–disease (curated): hypertriglyceridemia (Limited, GenCC)
• Clinical variants (ClinVar): 196 total
• MANE Select transcript: NM_001302998

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:18821
Approved symbol	LIPI
Name	lipase I
Location	21q11.2
Locus type	gene with protein product
Status	Approved
Aliases	PRED5, LPDL, CT17, mPA-PLA1beta, PLA1C
Ensembl gene	ENSG00000188992
Ensembl biotype	protein_coding
OMIM	609252
Entrez	149998

Gene structure

Transcript identifiers

Ensembl transcripts: 8 — 6 protein_coding, 1 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay

ENST00000344577, ENST00000400211, ENST00000536861, ENST00000614229, ENST00000679868, ENST00000680487, ENST00000680801, ENST00000681601

RefSeq mRNA: 7 — MANE Select: NM_001302998 NM_001302998, NM_001302999, NM_001303000, NM_001303001, NM_001379565, NM_001379566, NM_198996

CCDS: CCDS93076, CCDS93077, CCDS93078, CCDS93079, CCDS93080, CCDS93081

Canonical transcript exons

ENST00000681601 — 10 exons

Exon	Start	End
ENSE00001369084	14185961	14186069
ENSE00001371492	14181758	14181859
ENSE00001379335	14166362	14166451
ENSE00001634008	14152573	14152684
ENSE00001636528	14189034	14189419
ENSE00001684532	14163419	14163523
ENSE00001727035	14108813	14109080
ENSE00001796235	14144623	14144799
ENSE00002715027	14165223	14165390
ENSE00003914878	14210800	14210955

Expression profiles

Bgee: expression breadth ubiquitous, 102 present calls, max score 99.31.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.1973 / max 169.7840, expressed in 9 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
189756	0.1355	9
189757	0.0307	6
189755	0.0129	2
189753	0.0084	5
189752	0.0055	2
189754	0.0044	3

Top tissues by expression

225 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
corpus epididymis	UBERON:0004359	99.31	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	92.74	gold quality
cauda epididymis	UBERON:0004360	74.35	gold quality
caput epididymis	UBERON:0004358	70.45	gold quality
body of uterus	UBERON:0009853	65.57	gold quality
tibia	UBERON:0000979	65.43	gold quality
buccal mucosa cell	CL:0002336	63.96	gold quality
cortical plate	UBERON:0005343	63.38	gold quality
muscle layer of sigmoid colon	UBERON:0035805	62.33	gold quality
lower esophagus mucosa	UBERON:0035834	60.46	gold quality
left lobe of thyroid gland	UBERON:0001120	59.97	gold quality
ganglionic eminence	UBERON:0004023	59.06	gold quality
thyroid gland	UBERON:0002046	58.73	gold quality
endothelial cell	CL:0000115	57.81	gold quality
ectocervix	UBERON:0012249	56.96	gold quality
esophagus mucosa	UBERON:0002469	56.49	gold quality
uterus	UBERON:0000995	55.48	gold quality
lower lobe of lung	UBERON:0008949	55.13	silver quality
endocervix	UBERON:0000458	54.96	gold quality
right lobe of thyroid gland	UBERON:0001119	54.85	gold quality
cardiac muscle of right atrium	UBERON:0003379	54.34	gold quality
left ventricle myocardium	UBERON:0006566	54.23	gold quality
endometrium	UBERON:0001295	54.19	gold quality
kidney epithelium	UBERON:0004819	53.93	gold quality
epithelial cell of pancreas	CL:0000083	53.61	gold quality
tibialis anterior	UBERON:0001385	53.53	silver quality
upper arm skin	UBERON:0004263	53.52	gold quality
myometrium	UBERON:0001296	52.90	gold quality
calcaneal tendon	UBERON:0003701	52.02	silver quality
ileal mucosa	UBERON:0000331	51.77	silver quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	3.09

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

18 targeting LIPI, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-513B-5P	99.99	69.96	2150
HSA-MIR-33A-5P	99.99	68.62	1055
HSA-MIR-33B-5P	99.99	68.58	1062
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-1-3P	99.93	72.35	1914
HSA-MIR-206	99.93	72.50	1893
HSA-MIR-613	99.91	71.50	1710
HSA-MIR-10395-5P	99.86	67.35	676
HSA-MIR-148A-3P	99.74	73.77	1700
HSA-MIR-148B-3P	99.74	73.75	1700
HSA-MIR-152-3P	99.74	73.75	1703
HSA-MIR-586	99.65	70.40	2051
HSA-MIR-4499	99.62	67.29	1470
HSA-MIR-216A-5P	99.50	68.02	1288
HSA-MIR-372-5P	99.41	69.11	2299
HSA-MIR-6882-5P	99.35	71.13	1206
HSA-MIR-4528	99.18	69.77	1936

Literature-anchored findings (GeneRIF, showing 1)

• Different LIPI transcript variants present in Ewing family tumors (EFT) might be involved in the pathogenesis of EFT by signaling via these LPA receptors. (PMID:21132378)

Cross-species orthologs

30 orthologs

Organism	Symbol	Gene ID
danio_rerio	lipib	ENSDARG00000005332
danio_rerio		ENSDARG00000034667
mus_musculus	Lipi	ENSMUSG00000032948
rattus_norvegicus	Lipi	ENSRNOG00000033441
drosophila_melanogaster	Yp1	FBGN0004045
drosophila_melanogaster	Yp3	FBGN0004047
drosophila_melanogaster	Yp2	FBGN0005391
drosophila_melanogaster	CG5162	FBGN0030828
drosophila_melanogaster	CG6847	FBGN0030884
drosophila_melanogaster	CG7367	FBGN0031976
drosophila_melanogaster	CG13282	FBGN0032612
drosophila_melanogaster	CG6675	FBGN0032973
drosophila_melanogaster	CG6472	FBGN0034166
drosophila_melanogaster	CG10163	FBGN0035697
drosophila_melanogaster	CG10116	FBGN0036367
drosophila_melanogaster	CG5665	FBGN0036977
drosophila_melanogaster	sxe2	FBGN0038398
drosophila_melanogaster	CG4582	FBGN0039344
drosophila_melanogaster	CG6296	FBGN0039470
drosophila_melanogaster	CG6295	FBGN0039471
drosophila_melanogaster	CG17192	FBGN0039472
drosophila_melanogaster	CG17191	FBGN0039473
drosophila_melanogaster	CG6283	FBGN0039474
drosophila_melanogaster	CG6277	FBGN0039475
drosophila_melanogaster	CG6271	FBGN0039476
drosophila_melanogaster	CG34447	FBGN0085476
drosophila_melanogaster	CG34448	FBGN0085477
drosophila_melanogaster	CG14034	FBGN0250847
drosophila_melanogaster	CG4267	FBGN0264979
drosophila_melanogaster	CG18258	FBGN0265267

Paralogs (9): LIPG (ENSG00000101670), PLA1A (ENSG00000144837), LIPH (ENSG00000163898), LIPC (ENSG00000166035), LPL (ENSG00000175445), PNLIP (ENSG00000175535), PNLIPRP1 (ENSG00000187021), PNLIPRP3 (ENSG00000203837), PNLIPRP2 (ENSG00000266200)

Protein

Protein identifiers

Lipase member I — Q6XZB0 (reviewed: Q6XZB0)

Alternative names: Cancer/testis antigen 17, LPD lipase, Membrane-associated phosphatidic acid-selective phospholipase A1-beta

All UniProt accessions (4): A0A087WZG8, A0A2Q2TCK2, Q6XZB0, H0Y3S0

UniProt curated annotations — full annotation on UniProt →

Function. Hydrolyzes specifically phosphatidic acid (PA) to produce 2-acyl lysophosphatidic acid (LPA; a potent bioactive lipid mediator) and fatty acid. Does not hydrolyze other phospholipids, like phosphatidylserine (PS), phosphatidylcholine (PC) and phosphatidylethanolamine (PE) or triacylglycerol (TG).

Subunit / interactions. Interacts with heparin with a high affinity.

Subcellular location. Cell membrane. Secreted Cell membrane. Secreted.

Tissue specificity. Expressed in testis. Expressed exclusively at the connecting piece of the sperm.

Activity regulation. Inhibited by sodium vanadate.

Similarity. Belongs to the AB hydrolase superfamily. Lipase family.

Isoforms (8)

UniProt ID	Names	Canonical?
Q6XZB0-1	1, mPA-PLA1beta	yes
Q6XZB0-2	2, mPA-PLA1alpha
Q6XZB0-3	3, deltaE7.2
Q6XZB0-4	4, deltaE6.1
Q6XZB0-5	5, deltaE5
Q6XZB0-6	6, deltaE8-9
Q6XZB0-7	7, 7B+
Q6XZB0-8	8, deltaE2-3

RefSeq proteins (7): NP_001289927, NP_001289928, NP_001289929, NP_001289930, NP_001366494, NP_001366495, NP_945347 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000734	TAG_lipase	Family
IPR013818	Lipase	Domain
IPR016272	Lipase_LIPH	Family
IPR029058	AB_hydrolase_fold	Homologous_superfamily
IPR033906	Lipase_N	Domain

Pfam: PF00151

Enzyme classification (BRENDA):

• EC 3.1.1.111 — phosphatidylserine sn-1 acylhydrolase (BRENDA: 3 organisms, 14 substrates, 2 inhibitors, 0 Km, 0 kcat entries)
• EC 3.1.1.32 — phospholipase A1 (BRENDA: 55 organisms, 221 substrates, 99 inhibitors, 14 Km, 5 kcat entries)

Substrate kinetics (BRENDA)

10 substrates with measured Km, best-characterized 10. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
PHOSPHATIDYLCHOLINE	0.11–4	4
1-PALMITOYL-2-ARACHIDONOYLGLYCEROPHOSPHOCHOLINE	0.5	1
DIACYL-SN-GLYCERO-3-PHOSPHORYLCHOLINE	0.6	1
DIACYL-SN-GLYCERO-3-PHOSPHORYLETHANOLAMINE	0.92	1
DIACYL-SN-GLYCERO-3-PHOSPHORYLSERINE	1.19	1
PHOSPHATIDIC ACID	2.38	1
PHOSPHATIDYLGLYCEROL	0.0003	1
SOYBEAN LECITHIN	18.53	1
TRIACYLGLYCEROL	1.53	1
HIGH-DENSITY LIPOPROTEIN	—	0

Catalyzed reactions (Rhea), 1 shown:

• 1-hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-phosphate + H2O = 2-(9Z-octadecenoyl)-sn-glycero-3-phosphate + hexadecanoate + H(+) (RHEA:40943)

UniProt features (26 total): splice variant 9, disulfide bond 4, sequence variant 4, active site 3, glycosylation site 2, signal peptide 1, chain 1, mutagenesis site 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q6XZB0-F1	89.19	0.73

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (3): 159 (nucleophile); 183 (charge relay system); 253 (charge relay system)

Disulfide bonds (4): 436–455, 238–251, 275–286, 289–297

Glycosylation sites (2): 63, 396

Mutagenesis-validated functional residues (1):

Position	Phenotype
159	no activity.

Function

Pathways and Gene Ontology

Reactome pathways

5 pathways

ID	Pathway
R-HSA-1483166	Synthesis of PA
R-HSA-1430728	Metabolism
R-HSA-1483206	Glycerophospholipid biosynthesis
R-HSA-1483257	Phospholipid metabolism
R-HSA-556833	Metabolism of lipids

MSigDB gene sets: 44 (showing top): GOBP_PHOSPHOLIPID_METABOLIC_PROCESS, STAEGE_EWING_FAMILY_TUMOR, GOBP_ORGANOPHOSPHATE_METABOLIC_PROCESS, GOBP_ORGANOPHOSPHATE_BIOSYNTHETIC_PROCESS, GOBP_PHOSPHOLIPID_BIOSYNTHETIC_PROCESS, GOBP_GLYCEROLIPID_METABOLIC_PROCESS, GOBP_GLYCEROLIPID_BIOSYNTHETIC_PROCESS, GOBP_GLYCEROPHOSPHOLIPID_METABOLIC_PROCESS, GOBP_LIPID_METABOLIC_PROCESS, GOMF_GLYCOSAMINOGLYCAN_BINDING, DOUGLAS_BMI1_TARGETS_DN, GOBP_LIPID_BIOSYNTHETIC_PROCESS, GOBP_LIPID_CATABOLIC_PROCESS, GOMF_HEPARIN_BINDING, GOMF_SULFUR_COMPOUND_BINDING

GO Biological Process (3): phosphatidic acid biosynthetic process (GO:0006654), lipid catabolic process (GO:0016042), lipid metabolic process (GO:0006629)

GO Molecular Function (6): glycerophospholipase activity (GO:0004620), heparin binding (GO:0008201), carboxylic ester hydrolase activity (GO:0052689), lipase activity (GO:0016298), hydrolase activity (GO:0016787), metal ion binding (GO:0046872)

GO Cellular Component (4): obsolete extracellular space (GO:0005615), plasma membrane (GO:0005886), extracellular region (GO:0005576), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-4 pathways:

Category	Pathways
Glycerophospholipid biosynthesis	1
Phospholipid metabolism	1
Metabolism of lipids	1
Metabolism	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
hydrolase activity, acting on ester bonds	2
cellular anatomical structure	2
phosphatidic acid metabolic process	1
glycerophospholipid biosynthetic process	1
lipid metabolic process	1
catabolic process	1
primary metabolic process	1
phospholipase activity	1
glycosaminoglycan binding	1
sulfur compound binding	1
catalytic activity	1
cation binding	1
membrane	1
cell periphery	1

Protein interactions and networks

STRING

420 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
LIPI	GAS2L2	Q8NHY3	815
LIPI	GAS2	O43903	762
LIPI	APOA5	Q6Q788	761
LIPI	GAS2L1	Q99501	761
LIPI	HSPA13	P48723	750
LIPI	PRSS50	Q9UI38	696
LIPI	ACRBP	Q8NEB7	690
LIPI	PAGE5	Q96GU1	665
LIPI	ADAM2	P78326	621
LIPI	SAGE1	Q9NXZ1	606
LIPI	SPA17	Q15506	574
LIPI	MAGEC1	O60732	571
LIPI	ZBTB21	Q9ULJ3	553
LIPI	UMODL1	Q5DID0	542
LIPI	MAGEC2	Q9UBF1	507

IntAct

0 interactions, top by confidence:

BioGRID (4): LIPI (Synthetic Lethality), LIPI (Affinity Capture-MS), LIPI (Cross-Linking-MS (XL-MS)), LIPI (Affinity Capture-RNA)

ESM2 similar proteins: A0A0M3KKW3, A0A8B0RBM2, A2VBC4, A5PK46, B2D0J5, C0HLL3, D6WMZ8, D7EZN2, O88354, P00591, P06857, P0CH47, P0CH86, P0CH87, P0DMB4, P0DMB5, P0DPT0, P0DSI2, P16233, P17892, P18167, P27657, P29183, P35501, P35502, P49369, P50903, P51528, P52714, P53357, P54315, P54316, P54317, P54318, P81139, Q02157, Q06478, Q17RR3, Q3ZU95, Q5BKQ4

Diamond homologs: A0A0M3KKW3, A2VBC4, C0HLL3, O46559, P06857, P07867, P0CH47, P0CH86, P0CH87, P0DMB4, P0DMB5, P0DMB7, P0DMB8, P0DPT0, P0DSI2, P11150, P11602, P27656, P29183, P49369, P51528, P53357, P54315, P54316, P81139, Q02157, Q06478, Q3SZ79, Q3ZU95, Q5BKQ4, Q5XGE9, Q68KK0, Q6NYZ4, Q6Q249, Q6Q250, Q6Q251, Q6Q252, Q6XZB0, Q7M3V3, Q7M3V4

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

196 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	123
Likely benign	40
Benign	23

Top pathogenic / likely-pathogenic (0)

SpliceAI

2226 predictions. Top by Δscore:

Variant	Effect	Δscore
21:14163417:A:AC	donor_gain	1.0000
21:14163418:C:CC	donor_gain	1.0000
21:14163418:CTA:C	donor_gain	1.0000
21:14181744:T:TA	donor_gain	1.0000
21:14181858:ACC:A	acceptor_loss	1.0000
21:14181860:CTGG:C	acceptor_loss	1.0000
21:14181861:T:A	acceptor_loss	1.0000
21:14144617:TCTTA:T	donor_loss	0.9900
21:14144618:CTTAC:C	donor_loss	0.9900
21:14144619:TTAC:T	donor_loss	0.9900
21:14144620:TA:T	donor_loss	0.9900
21:14144621:ACC:A	donor_loss	0.9900
21:14144622:CCTTT:C	donor_gain	0.9900
21:14144796:CTTT:C	acceptor_gain	0.9900
21:14144800:C:CC	acceptor_gain	0.9900
21:14163436:C:CT	donor_gain	0.9900
21:14163436:CCA:C	donor_gain	0.9900
21:14181860:C:CC	acceptor_gain	0.9900
21:14185955:TTTTA:T	donor_loss	0.9900
21:14185956:TTTA:T	donor_loss	0.9900
21:14185957:TTA:T	donor_loss	0.9900
21:14185958:TAC:T	donor_loss	0.9900
21:14185959:A:C	donor_loss	0.9900
21:14185960:C:CT	donor_loss	0.9900
21:14185961:C:G	donor_loss	0.9900
21:14186065:TGCTT:T	acceptor_gain	0.9900
21:14193763:A:T	acceptor_gain	0.9900
21:14181741:AAAT:A	donor_gain	0.9800
21:14181855:AAGAC:A	acceptor_gain	0.9800
21:14181857:GAC:G	acceptor_gain	0.9800

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000011911 (21:14196807 C>A,T), RS1000029523 (21:14186777 C>T), RS1000036434 (21:14152211 T>C), RS1000053824 (21:14135050 G>A), RS1000086720 (21:14151998 G>A), RS1000108814 (21:14155844 G>A), RS1000109734 (21:14117766 C>T), RS1000114636 (21:14177077 G>A,T), RS1000182897 (21:14202633 T>G), RS1000214901 (21:14146225 A>G,T), RS1000254514 (21:14190421 T>G), RS1000275145 (21:14182662 T>A), RS1000282983 (21:14189964 G>C,T), RS1000292077 (21:14112447 T>C), RS1000359972 (21:14138246 C>A)

Disease associations

OMIM: gene MIM:609252 | disease phenotypes: MIM:145750

GenCC curated gene-disease

Disease	Classification	Inheritance
hypertriglyceridemia	Limited	Autosomal dominant

Mondo (2): hypertriglyceridemia 1 (MONDO:0007788), hypertriglyceridemia (MONDO:0005347)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D015228	Hypertriglyceridemia	C18.452.584.500.500.851

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

5 total (human), top 5 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	increases methylation	1
Cadmium	decreases expression, increases abundance	1
Endosulfan	decreases reaction, decreases expression	1
Tetrachlorodibenzodioxin	decreases expression, decreases reaction	1
Cadmium Chloride	decreases expression, increases abundance	1

Clinical trials (associated diseases)

233 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00246636	PHASE4	COMPLETED	Evaluation of Efficacy and Safety of Omacor (Omega-3-acid Ethyl Esters) as Add-on Therapy in Hypertriglyceridemic Subjects Treated With Antara (Fenofibrate) Followed by an 8-week Extension
NCT00286234	PHASE4	COMPLETED	Niacin, N-3 Fatty Acids and Insulin Resistance
NCT00346697	PHASE4	COMPLETED	Omega-3 Fatty Acids for High Triglycerides in HIV-infected Patients
NCT00397358	PHASE4	WITHDRAWN	Effect of Extraneal (Icodextrin)on Triglyceride Levels in PD Patients
NCT00473655	PHASE4	COMPLETED	Effect of Rosuvastatin on Triglyceride Levels in Mexican Hypertriglyceridemic Patients
NCT00632840	PHASE4	COMPLETED	Pharmacological Regulation of Fat Transport in Metabolic Syndrome
NCT00745407	PHASE4	COMPLETED	Effects of Fenofibrate on Adipocytokine Levels In Hypertriglyceridemic Patients
NCT00758927	PHASE4	UNKNOWN	The Effects of Omega-3 Fatty Acid (OMACOR) on the Low-density Lipoprotein (LDL) Sub-fraction in Type 2 Diabetic Patients
NCT00891293	PHASE4	COMPLETED	A Second Open-Label Extension of a Double-Blind, Parallel, Phase IV Study to Assess the Efficacy and Safety of Adjunctive Lovaza® (Formerly Known as Omacor®) Therapy in Hypertriglyceridemic Subjects Treated With Antara™
NCT00931879	PHASE4	COMPLETED	Lovaza® and Microvascular Function in Type 2 Diabetes
NCT00934219	PHASE4	UNKNOWN	Triglyceride Lowering Study
NCT01003847	PHASE4	COMPLETED	Differential Metabolic Effects of Fenofibrate and Fatty Acid
NCT01010399	PHASE4	COMPLETED	Boosted Lexiva With Lovaza Adjunctive Therapy in Hypertriglyceridemic, HIV-Infected Subjects
NCT01180764	PHASE4	WITHDRAWN	Effects of Lovaza on High Density Lipoprotein (HDL) Composition and Function in Hypertriglyceridemia
NCT01462877	PHASE4	COMPLETED	A Study to Evaluate Fenofibrate Combination With Statin in Chinese Patients With Dyslipidemic
NCT01480687	PHASE4	UNKNOWN	Fish Oil Supplementation and Vascular Function in Hypertensive Patients With Hypertriglyceridemia
NCT01527747	PHASE4	SUSPENDED	Effects of DPP-4 Inhibition on Triglycerides
NCT01569724	PHASE4	COMPLETED	Carbohydrate Metabolism Disorder Frequency in Hypertriglyceridemia Induced by Bexarotene of Cutaneous T Cell Lymphoma
NCT01625442	PHASE4	COMPLETED	Crocus Sativus (Saffron) and Berberis Vulgaris (Barberry Fruit) in Metabolic Syndrome
NCT01660932	PHASE4	COMPLETED	Vascular and Metabolic Effects of Omega-3 Fatty Acids
NCT01666041	PHASE4	COMPLETED	Vascular and Metabolic Effects of Fenofibrate/Omega vs Fenofibrate
NCT02015988	PHASE4	UNKNOWN	Simvastatin and Fenofibrate vs Simvastatin Alone in Patients With Type 2 Diabetes Mellitus and Acute Coronary Syndrome
NCT02926027	PHASE4	COMPLETED	Effect of Vascepa on Improving Coronary Atherosclerosis in People With High Triglycerides Taking Statin Therapy
NCT03120299	PHASE4	COMPLETED	The Effect of Omega-3 FA on Hypertriglyceridemia in Patients With T2DM(OCEAN)
NCT03342807	PHASE4	UNKNOWN	Intravenous Administration of Insulin and Plasma Exchange on Triglyceride Levels in Early Stage of Hypertriglyceridemia-induced Pancreatitis
NCT03501680	PHASE4	UNKNOWN	Intensive Insulin for Severe/Moderate Hypertriglyceridemia Pancreatitis.
NCT05487833	PHASE4	UNKNOWN	Insulin and Standard Management in Hypertriglyceridemic Acute Pancreatitis
NCT06129526	PHASE4	UNKNOWN	Study of the Efficacy and Safety of EPA in Patients With Type-2 Diabetes
NCT00092560	PHASE3	COMPLETED	Two Investigational Drugs in Patients With Mixed Hyperlipidemia (0653-036)
NCT00092573	PHASE3	COMPLETED	Study of Ezetimibe and Fenofibrate in Patients With Mixed Hyperlipidemia (0653-036)(COMPLETED)
NCT00093899	PHASE3	COMPLETED	A Study to Evaluate an Investigational Drug in Patients With Mixed Hyperlipidemia (0653A-071)(COMPLETED)
NCT00134498	PHASE3	COMPLETED	A Study Comparing The Efficacy & Safety Of Torcetrapib/Atorvastatin And Atorvastatin In Subjects With High Triglycerides
NCT00231621	PHASE3	TERMINATED	A Study on Efficacy and Safety of Topiramate in Treatment of Obese Subjects With Dyslipidemia
NCT00246701	PHASE3	COMPLETED	Evaluation of Efficacy and Safety of Combined Omacor (Omega-3-acid Ethyl Esters) and Simvastatin Therapy in Hypertriglyceridemic Subjects
NCT00435045	PHASE3	COMPLETED	Evaluation of Efficacy and Safety of Omacor, Co-Administered With Atorvastatin, in Subjects With Hypertriglyceridemia
NCT00560430	PHASE3	COMPLETED	Regulation of Inflammatory Parameters by Telmisartan in Hypertensive Patients
NCT00887653	PHASE3	COMPLETED	Changes in Lipids and Safety of Raltegravir in HIV+ Patients With Hyperlipidemia While on Current Standard Therapy
NCT00903409	PHASE3	COMPLETED	Open-Label Extension of a Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lovaza® and Simvastatin Therapy in Hypertriglyceridemic Subjects
NCT00973271	PHASE3	WITHDRAWN	Diazoxide Choline Controlled-Release Tablet (DCCR) for Very High Triglycerides
NCT01047501	PHASE3	COMPLETED	Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL)